Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $114,275.00 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Todd Watanabe sold 4,375 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the transaction, the insider owned 717,203 shares in the company, valued at $18,733,342.36. The trade was a 0.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arcutis Biotherapeutics Trading Down 4.3%

NASDAQ:ARQT opened at $25.29 on Friday. The company has a market capitalization of $3.16 billion, a P/E ratio of 120.43 and a beta of 1.49. The company has a current ratio of 2.92, a quick ratio of 2.46 and a debt-to-equity ratio of 0.46. Arcutis Biotherapeutics, Inc. has a 12 month low of $13.69 and a 12 month high of $31.77. The firm has a fifty day simple moving average of $26.05 and a 200-day simple moving average of $24.69.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.05. The firm had revenue of $129.86 million for the quarter, compared to the consensus estimate of $118.85 million. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. On average, equities research analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of institutional investors have recently modified their holdings of the stock. Citizens Financial Group Inc. RI acquired a new position in shares of Arcutis Biotherapeutics in the 2nd quarter valued at about $922,000. BlackRock Inc. acquired a new stake in Arcutis Biotherapeutics during the second quarter worth about $276,502,000. Deutsche Bank AG acquired a new stake in Arcutis Biotherapeutics during the second quarter worth about $10,034,000. Persistent Asset Partners Ltd purchased a new position in Arcutis Biotherapeutics during the second quarter valued at approximately $227,000. Finally, Bank of New York Mellon Corp purchased a new position in Arcutis Biotherapeutics during the second quarter valued at approximately $8,655,000.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ARQT. Weiss Ratings upgraded Arcutis Biotherapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday. Morgan Stanley increased their price target on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday. Guggenheim raised their price target on shares of Arcutis Biotherapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen upgraded shares of Arcutis Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Needham & Company LLC upped their price objective on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Arcutis Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $35.57.

Arcutis Biotherapeutics News Roundup

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong second-quarter performance: Arcutis reported adjusted EPS of $0.11, exceeding estimates of $0.06–$0.09 and improving from a $0.13 loss a year earlier. Revenue rose 59% year over year to $129.9 million, beating the $118.9 million consensus estimate. Arcutis Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Raised sales outlook and expanding ZORYVE opportunity: Management increased 2026 net product-sales guidance to $525 million–$540 million. ZORYVE also gained an expanded pediatric plaque-psoriasis approval, while the FDA accepted an application for use in infants with atopic dermatitis. Arcutis Second-Quarter 2026 Financial Results
• Positive Sentiment: Analyst support remains favorable: Needham raised its price target from $36 to $40 and reiterated a Buy rating. HC Wainwright’s 2027 estimates project quarterly EPS rising from $0.08 in the first quarter to $0.48 in the fourth quarter, suggesting expectations for continued earnings growth. Benzinga analyst report
• Neutral Sentiment: Commercial leadership changes: Arcutis announced key changes to its commercial leadership team. The move could support execution, but investors may initially view management transitions as an operational uncertainty. Arcutis Announces Key Commercial Leadership Changes
• Neutral Sentiment: Insider selling was limited and prearranged: Three executives sold a combined 6,560 shares to cover tax withholding on vested equity awards under Rule 10b5-1 plans, reducing the bearish significance of the transactions.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.